A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

What is the purpose of this trial?

This is a Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB928 in combination with mFOLFOX in participants with advanced metastatic gastroesophageal Cancer (GEC) or colorectal cancer (CRC).



Arcus Biosciences, Inc.

Start Date: 02/07/2019

End Date: 11/30/2020

Last Updated: 03/07/2019

Study HIC#: 2000024289

Get Involved

For more information about this study, contact:
Kirsten Dooley
+1 203-764-8412
kirsten.dooley@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Michael Cecchini

Principal Investigator

Sub-Investigators